Sanofi agreed to acquire Dynavax Technologies for $2.2 billion in cash, adding the commercial hepatitis B vaccine Heplisav‑B and a clinical‑stage shingles candidate to its portfolio. The transaction closes Sanofi’s second billion‑dollar vaccine purchase of 2025 and gives the French group a differentiated hepatitis B offering versus GSK. MedCity News reported the deal and cited Dynavax’s marketed vaccine as the primary near‑term commercial asset. The acquisition comes alongside separate program news at Sanofi; regulatory setbacks for other assets were disclosed in parallel coverage. The deal price represented a premium to Dynavax’s recent share price and consolidates Sanofi’s vaccine strategy ahead of 2026 product launches. Industry watchers will monitor integration risks, headcount and manufacturing commitments tied to Heplisav‑B and the shingles program.